1. Home
  2. RCAT vs ABVX Comparison

RCAT vs ABVX Comparison

Compare RCAT & ABVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • RCAT
  • ABVX
  • Stock Information
  • Founded
  • RCAT 2002
  • ABVX 2013
  • Country
  • RCAT United States
  • ABVX France
  • Employees
  • RCAT N/A
  • ABVX 69
  • Industry
  • RCAT Wholesale Distributors
  • ABVX
  • Sector
  • RCAT Industrials
  • ABVX
  • Exchange
  • RCAT Nasdaq
  • ABVX Nasdaq
  • Market Cap
  • RCAT N/A
  • ABVX 407.6M
  • IPO Year
  • RCAT 2017
  • ABVX N/A
  • Fundamental
  • Price
  • RCAT $5.89
  • ABVX $6.43
  • Analyst Decision
  • RCAT Strong Buy
  • ABVX Buy
  • Analyst Count
  • RCAT 2
  • ABVX 8
  • Target Price
  • RCAT $8.50
  • ABVX $34.63
  • AVG Volume (30 Days)
  • RCAT 4.0M
  • ABVX 324.9K
  • Earning Date
  • RCAT 03-31-2025
  • ABVX 03-24-2025
  • Dividend Yield
  • RCAT N/A
  • ABVX N/A
  • EPS Growth
  • RCAT N/A
  • ABVX N/A
  • EPS
  • RCAT N/A
  • ABVX N/A
  • Revenue
  • RCAT $16,468,647.00
  • ABVX $11,172,999.00
  • Revenue This Year
  • RCAT $113.68
  • ABVX $306.91
  • Revenue Next Year
  • RCAT $206.40
  • ABVX N/A
  • P/E Ratio
  • RCAT N/A
  • ABVX N/A
  • Revenue Growth
  • RCAT 95.46
  • ABVX 135.94
  • 52 Week Low
  • RCAT $0.75
  • ABVX $5.50
  • 52 Week High
  • RCAT $15.27
  • ABVX $16.63
  • Technical
  • Relative Strength Index (RSI)
  • RCAT 45.85
  • ABVX 42.38
  • Support Level
  • RCAT $5.44
  • ABVX $5.60
  • Resistance Level
  • RCAT $6.20
  • ABVX $7.85
  • Average True Range (ATR)
  • RCAT 0.46
  • ABVX 0.58
  • MACD
  • RCAT 0.23
  • ABVX -0.01
  • Stochastic Oscillator
  • RCAT 76.16
  • ABVX 36.89

About ABVX Abivax SA American

Abivax SA is a France-based clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Company is evaluating its drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis. Its initial focus is on inflammatory bowel diseases, chronic conditions involving inflammation of the gastrointestinal tract, of which the two common forms are UC and CD.

Share on Social Networks: